Industry News: Volume 2, Issue 7

AscellaHealth Launches Expanded Website: User-Friendly Content on Global Specialty Pharmacy and Healthcare Services for Patients, Payers, Life Sciences and Providers

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces the unveiling of a more robust, streamlined website with easy-to-navigate content featuring its innovative programs and services for key market sectors: patients – the focal point for all AscellaHealth initiatives; payers, including health plans and employers; life sciences, spanning pharmaceutical and biotech manufacturers; and providers comprising health systems, prescribers and specialty pharmacies. The newly designed website supports innovative opportunities to deliver the best possible experience for patients with chronic or complex conditions requiring specialty medications or cell and gene therapies, as well as alternative financial solutions that address the steep cost of therapies.

“By enhancing our digital presence and customizing the content for key audience stakeholders, we take another step forward in positioning our fast-growth company as a leader in end-to-end Specialty Pharmaceutical services that improve access to medications for patients, optimize clinical outcomes and pioneer payment and pricing models that adequately balance access and affordability, while sufficiently valuing curative therapies,” says Dea Belazi, president and CEO, AscellaHealth. “Our comprehensive HUB services for life science companies and clinical patient support capabilities help to simplify communications between prescribers, patients and pharmacies, improve access and decrease medication fulfillment times. We’re also very proud of our custom and innovative copay and financial assistance solutions which enhance patient affordability of high-cost specialty medications to increase therapy adherence and brand loyalty.”

AscellaHealth’s state-of-the-art programs and services include:

  • Limited distribution drug fulfillment
  • Pre-commercialization and market access
  • Group purchasing services and drug rebate programs
  • Patient Support and HUB Services
  • Financial and copay assistance programs
  • Specialty Pharmacy and Medical Benefit Management

Belazi adds, “This redesigned website gives visitors an inside look at AscellaHealth’s patient-first solutions and demonstrates our industry leadership in Specialty Pharmacy. Newcomers to our site, as well as longtime clients and stakeholders, will appreciate our expanded programs to help manufacturers extend the value of their products and increase outcomes, while supporting payers and providers in their efforts to reduce administrative waste and manage high-cost specialty spend.”

Visit the newly designed website at www.AscellaHealth.com.

About AscellaHealth LLC

AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving patients, payers, life sciences and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. An Inc. 5000 2021 winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit www.AscellaHealth.com.

Contacts

Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

AscellaHealth Expands Pharmaceutical Services for Life Sciences: Pre-Commercialization and Outsourced Market Access Solutions and Patient Support & HUB Services Ensure Optimal Access and Clinical Outcomes

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces a comprehensive suite of Specialty Pharmacy (SP) services, including pre-commercialization, outsourced market access, wholesale, 3PL, limited distribution drug (LDD) fulfillment, and custom Patient Support and HUB Services. AscellaHealth now serves as an extension of the pharmaceutical company’s trade or market access team with outsourced market access solutionsthat provide strategic payer expertise, utilization management, pull-through programs and real-time data access.

AscellaHealth capabilities span the entire product life cycle and prescription process, streamlining communications between prescriber, patient and pharmacy to eliminate barriers, decrease time-to-fill, enhance the patient journey and optimize outcomes.

“As a true industry partner with a thorough understanding of the payer mix and value, AscellaHealth’s outsourced market access solutionsamplify the activities of a company’s trade and market access team,” says Dea Belazi, president and CEO, AscellaHealth. “Our deep bench experience and expertise in payer reimbursement and strategy development, in-depth understanding of the competitive environment, programs designed to drive branded volume and data-driven cost savings analyses result in optimal patient access to products in major specialty and rare disease categories.”

The AscellaHealth service portfolio also features customized clinical support programs and interventions that result in better compliance to therapy. As Belazi explains, “Our LDD pharmacy and partners offer centers of excellence across many specialty conditions and high touch capabilities to further improve the patient experience, decrease time-to-fill and optimize outcomes.”

AscellaHealth’s pre-commercialization and market access solutions ensure that products are brought to market successfully, eliminating barriers so patients can access therapy when they need it most. AscellaHealth’s LDD fulfillment model ensures patients can seamlessly access medications and obtain the high touch support they need.

Belazi adds, “Our patient support begins when the prescriber submits an enrollment for their patient. From there we coordinate benefits verification, ensure the medication reaches the patient in a timely manner and implement key interventions at key points in therapy. This includes side effects management, with patient engagement initiatives throughout the process for optimal outcomes. Our goal is to eliminate every possible barrier to achieving the best possible outcome for every specialty or rare disease patient.”

AscellaHealth’s comprehensive portfolio of services for Life Sciences are customizable based on client needs, available “a la carte” and include:

  • Pre-Commercialization Strategies
  • Outsourced Market Access Solutions
  • Wholesale, Distribution and 3PL Services
  • LDD Fulfillment
  • Custom Compliance & Persistency Programs
  • Streamlined Prior Authorizations
  • Technology-based Patient Engagement
  • Copay and Financial Assistance Programs
  • Real-time Rx Data and Analytics

“Our full suite of tailored services for pharmaceutical manufacturers are designed to optimize product access, increase clinical outcomes and enhance quality of life for patients with specialty conditions or rare or orphan diseases,” Belazi concludes.

About AscellaHealth LLC
AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. An Inc. 5000 2021 winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit www.AscellaHealth.com.

Contacts

Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

Celebrate Medical Heroes By Joining A Free Virtual Activity Challenge This January

CISCRP’s 4th Annual Medical Heroes Appreci-a-thon Event Promotes Staying Active While Learning About the Importance of Clinical Research Participation.

BOSTON (PRWEB) December 28, 2021– The Center for Information and Study on Clinical Research Participation (The Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organization dedicated to educating and informing the public about the clinical research process, announced today its 4th annual Medical Heroes Appreci-a-thon event. This is a free, virtual activity challenge that is open to the public and will be held January 3rd-31st. The Medical Heroes Appreci-a-thon brings the public and global clinical research community together to express their appreciation for all “Medical Heroes” — clinical trial volunteers, medical and healthcare professionals, and researchers.

Racers can log their activity throughout the month of January, with each measurement of activity converted into
miles that will pin-point teams on the virtual course. This year’s virtual racecourse will wrap around the coastline of Oahu, with scenic views for participants to enjoy every mile.

Hear experiences from past Appreci-a-thon participants:

“Appreci-a-thon is a fun way to give back, learn about clinical research, and honor Medical Heroes.”

“This challenge is a great way to stay connected with friends, family, and colleagues!”

The Medical Heroes Appreci-a-thon virtual activity challenge starts January 3rd and runs through January 31st.
Participants can register at https://www.ciscrp.org/events/med-hero-virtual-appreci-a-thon-2022/

Contact Information
Joan Chambers
CISCRP
http://www.ciscrp.org
617-725-2750×202

Biden to make 1B COVID tests available for free online, doubling previous 500M pledge

By Andrea Park

FierceBiotech.com- After facing a flood of criticism for his administration’s largely vaccine-centric COVID-19 response plan, President Joe Biden has made moves in recent months to make diagnostic tests more widely available.

To read the article in its entirety, click here.

Some evidence shows omicron appears in your throat first. Should at-home Covid tests change?

By Kaitlin Sullivan

NBCNews.com- As omicron cases continue to sweep the United States, the Food and Drug Administration is being urged to gather more information about how well at-home Covid-19 tests are able to detect the variant.

Evidence suggests the omicron variant of the virus may appear in the throat before it shows up in the nose. For this reason, there’s been pressure on the FDA to recommend swabbing the throat with the nasal swabs. But medical experts argue that anecdotes from people who test negative with a nasal swab at home but then test positive with a throat swab can be misleading. FDA officials say there isn’t enough data to support the practice.

To read the article in its entirety, click here.

Whether we’ll need yearly boosters remains an open question, Fauci says

By Erika Edwards

NBCNews.com- Dr. Anthony Fauci says it’s conceivable that people may need to get Covid vaccine booster shots every year or two, but what variant the vaccine would target remains an open question.

In an ideal world, however, scientists hope to develop a shot that would protect against all future variants of the coronavirus, as well as other types of coronaviruses that cause other diseases, Fauci, the director of the National Institute of Allergy and Infectious Diseases, told NBC News.

To read the article in its entirety, click here.

US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikes

By Fraiser Kansteiner

FiercePharma.com- With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. Public and political scrutiny didn’t stop many of the world’s top drugmakers from partaking in the customary practice. Still, a shot at “historic” drug pricing reform could finally be within reach in the U.S., one watchdog figures.

To read the article in its entirety, click here.

Fending off heart disease by blocking how immune cells ‘smell’ their surroundings

By Angus Liu 

FierceBiotech.com – The buildup of fatty substances on the artery walls, known as atherosclerosis, involves inflammatory processes and can cause various cardiovascular diseases. Now, scientists at the La Jolla Institute for Immunology (LJI) have shed light on how targeting garbage-cleaning immune cells called macrophages might reverse or prevent the clogging problem.

To read the article in its entirety, click here.

Australia has decided to ‘let Covid rip.’ Is that a good idea?

By Nick Baker

NBCNews.com– As 2021 drew to a close, many Australians were cautiously optimistic that the worst of the Covid-19 pandemic was behind them.

The country had surpassed ambitious vaccine targets, meaning its rolling lockdowns could cease, both internal and international borders would reopen, and as Prime Minister Scott Morrison declared, it was now possible to “live with this virus.”

To read the article in its entirety, click here.

JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space

By Gareth Macdonald

FierceBiotech.com – Resurgent demand was a common theme for CROs presenting at the J.P. Morgan Healthcare Conference with Icon, Syneos and PPD owner Thermo Fisher daring to look beyond the pandemic toward changing industry needs.

To read the article in its entirety, click here.

Leave a Reply

Top